ArticleNeuro-oncology2014
IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection.
Article in Neuro-oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03542409 (Assessment of Safety and Feasibility of Preoperative and Intraoperative Image-Guided Resection of Gliomas and Tumor Region-Specific Biomarker Correlation), which is not on this map. Cited by 252 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessment of Safety and Feasibility of Preoperative and Intraoperative Image-Guided Resection of Gliomas and Tumor Region-Specific Biomarker Correlation
Who cites it
252 citing papers in PubMed, 5 syntheses or guidelines pooled it, 464 citations in OpenAlex.
- Supramaximal versus gross total resection in Glioblastoma, IDH wild-type and Astrocytoma, IDH-mutant, grade 4, effect on overall and progression free survival: systematic review and meta-analysis.Journal of neuro-oncology · 2023Pooled it
- Seizure outcome after resection of insular glioma: a systematic review, meta-analysis, and institutional experience.Journal of neurosurgery · 2023Pooled it
- Reliability of intraoperative ultrasound in detecting tumor residual after brain diffuse glioma surgery: a systematic review and meta-analysis.Neurosurgical review · 2020Pooled it
- A systematic review and meta-analysis of supratotal versus gross total resection for glioblastoma.Journal of neuro-oncology · 2020Pooled it
- Supratotal resection in glioma: a systematic review.Neuro-oncology · 2019Pooled it
- Intraoperative assessment of tumor margins during glioma resection by desorption electrospray ionization-mass spectrometry.Proceedings of the National Academy of Sciences of the United States of America · 2017Trial
- Contemporary surgical strategies for resection of intracranial gliomas.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Comparing artificial intelligence and physician performance in predicting IDH mutation status in glioma.NPJ digital medicine · 2026Article
- Lower-grade glioma imaging volumes and survival: a single-institution analysis of 90 patients after resection using intraoperative MRI.Journal of neuro-oncology · 2026Article
- Radiomics of T2-weighted MRI for pretreatment prediction of prognosis and temozolomide chemosensitivity in glioma.BMC cancer · 2026Article
- Review
- Analysis of outcomes of patients with oligodendroglioma with focus on volumetric reduction.Neuro-oncology practice · 2025Article
- Adoption of the T2-FLAIR Mismatch Sign among Radiologists: How Well Are We Doing?AJNR. American journal of neuroradiology · 2025Article
- Whole-tumor histogram analysis of diffusion weighted imaging, diffusion kurtosis imaging, and intravoxel incoherent motion for adult diffuse glioma genotyping.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Multi-site retrospective analysis of diffusion and perfusion magnetic resonance imaging correlates to glioma characteristics derived from radio-pathomic maps.Neuro-oncology · 2025Article
- Role of Multiparametric Ultrasound in Predicting the IDH Mutation in Gliomas: Insights from Intraoperative B-Mode, SWE, and SMI Modalities.Journal of clinical medicine · 2025Article
- Do the benefits of IDH mutations in high-grade glioma persist beyond the first recurrence? A multi-institutional retrospective analysis.Journal of neuro-oncology · 2025Article
- A role for early surgical intervention in childhood low-grade glioma? Illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Glioblastoma at the crossroads: current understanding and future therapeutic horizons.Signal transduction and targeted therapy · 2025Review
- Ultra-rapid droplet digital PCR enables intraoperative tumor quantification.Med (New York, N.Y.) · 2025Article
192 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
17 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundIDH1 gene mutations identify gliomas with a distinct molecular evolutionary origin. We sought to determine the impact of surgical resection on survival after controlling for IDH1 status in malignant astrocytomas-World Health Organization grade III anaplastic astrocytomas and grade IV glioblastoma.
methodsClinical parameters including volumetric assessment of preoperative and postoperative MRI were recorded prospectively on 335 malignant astrocytoma patients: n = 128 anaplastic astrocytomas and n = 207 glioblastoma. IDH1 status was assessed by sequencing and immunohistochemistry.
resultsIDH1 mutation was independently associated with complete resection of enhancing disease (93% complete resections among mutants vs 67% among wild-type, P < .001), indicating IDH1 mutant gliomas were more amenable to resection. The impact of residual tumor on survival differed between IDH1 wild-type and mutant tumors. Complete resection of enhancing disease among IDH1 wild-type tumors was associated with a median survival of 19.6 months versus 10.7 months for incomplete resection; however, no survival benefit was observed in association with further resection of nonenhancing disease (minimization of total tumor volume). In contrast, IDH1 mutants displayed an additional survival benefit associated with maximal resection of total tumor volume (median survival 9.75 y for >5 cc residual vs not reached for <5 cc, P = .025).
conclusionsThe survival benefit associated with surgical resection differs based on IDH1 genotype in malignant astrocytic gliomas. Therapeutic benefit from maximal surgical resection, including both enhancing and nonenhancing tumor, may contribute to the better prognosis observed in the IDH1 mutant subgroup. Thus, individualized surgical strategies for malignant astrocytoma may be considered based on IDH1 status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.